|
 |
Tradename |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Mabthera |
Argentina, Australia, Austria, Belgium, Chile, Colombia, Croatia, Denmark, Ecuador, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Mexico, Morocco, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Tunisia, Turkey, United Arab Emirates, Venezuela |
|
Novex |
Argentina |
|
Reditux |
Chile, Peru |
|
Rigetuxer |
Mexico |
|
Rituxan |
Canada, Japan, United States of America |
|
Rituximab |
New Zealand |
|
Rixathon |
Belgium, France, Germany, Great Britain, Spain, Switzerland |
|
Truxima |
Belgium, Canada, France, Germany, Great Britain, Spain, United States of America |
|
|
 |
 |
References : Rituximab |
|
|
Type |
Publication |
| 2296 |
Manufacturer |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 2825 |
Journal |
Mueller C, Dietel E, Heynen S, Nalenz H, Goldbach P, Mahler H, Schmidt J, Grauschopf U, Schoenhammer K.
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials.
Int J Pharm Compound 2015 ; 19, 3: 261-267. |
| 2881 |
Poster |
Jaccoulet E, Guirao S, Morand K, Astier A, Paul M.
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab.
SFPO Congress 2009 |
| 3323 |
Journal |
Paul M, Vieillard V, Jaccoulet E, Astier A.
Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Int J Pharm 2012 ; 436, 1-2: 282-290. |
| 4016 |
Journal |
Vieillard V, Paul M, Ibrahim T, Astier A.
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag.
Ann Pharm Fr 2017 ; 75, 6: 420-435. |
| 4040 |
Journal |
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M.
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
J Oncol Pharm Practice 2017 ;25,2: 269-278 |
| 4676 |
Poster |
Borišek R, Šmid I.
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days.
EAHP Congress Vienna 2022 |
| 4708 |
Journal |
Borišek R, Mischo A, Šmid I.
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage.
Drugs R D 2022 ; 22,3: 225–234 |
| 4740 |
Manufacturer |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021
Roche Products Limited 2021 |
|
|
